Celularity Inc. (GXGX) Stock Analysis
DELISTED 2021
What happened to Celularity Inc. (GXGX) stock?
Celularity Inc. (GXGX) no longer trades on public markets. It was delisted in July 2021. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Celularity Inc. (GXGX) trades at $10.20. GX Acquisition Corp. is a blank check company focused on merging with or acquiring another business. Market cap: $1.48B, Sector: Financial services.
Last analyzed: Mar 16, 2026Analyst Coverage for GXGX: GXGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GXGX against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Celularity Inc. (GXGX) Financial Services Profile
GX Acquisition Corp. (GXGX) is a special purpose acquisition company (SPAC) aiming to identify and merge with a private entity, offering investors exposure to a potentially high-growth business. As a shell company, it currently lacks operational revenue and is focused on deal origination within the financial services sector.
What Is the Investment Thesis for GXGX?
Investing in GXGX (Celularity Inc.) involves inherent risks and potential rewards associated with SPAC transactions. The company's success hinges on its ability to identify and integrate a high-growth target, Celularity. Key value drivers include the successful development and commercialization of Celularity's biotechnology products. Ongoing: The company's financial performance and stock valuation will be closely tied to the progress of Celularity's clinical trials, regulatory approvals, and market adoption of its therapies. Investors should carefully consider the risks associated with SPAC investments, including potential dilution, market volatility, and the execution challenges of integrating acquired businesses. The company's negative P/E ratio of -0.41 and a profit margin of -198.7% indicate that it is not currently profitable.
Based on FMP financials and quantitative analysis
GXGX Key Highlights
Market capitalization of $1.48B, reflecting investor valuation of the company's potential.
- Negative P/E ratio of -0.41, indicating the company is currently not profitable.
- Profit margin of -198.7%, highlighting significant expenses relative to revenue.
- Gross margin of 55.3%, suggesting a strong potential for profitability if expenses are managed effectively.
- No dividend yield, as the company is focused on reinvesting earnings for growth.
Who Are GXGX's Competitors?
GXGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DEH D8 Holdings Corp. | $11.57 | +4.23% | $1.56B | 44 |
| ENFA 890 5th Avenue Partners, Inc. | $9.62 | -2.93% | $1.34B | 46 |
| ENVI Environmental Impact Acquisition Corp. | $8.82 | +2.92% | $1.34B | 44 |
| FATH Fathom Digital Manufacturing Corporation | $5.05 | -4.17% | $34.7M | 38 |
| APXTW Apex Treasury Corporation | $0.35 | -5.41% | $1.89B | 66 |
| APXT Apex Technology Acquisition Corp. | $10.12 | -0.05% | $1.89B | 64 |
| APXTU Apex Treasury Corporation | $10.26 | +0.39% | $1.89B | 64 |
| IVAN Ivanhoe Capital Acquisition Corp. | $7.68 | -2.17% | $2.69B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GXGX's Key Strengths?
Experienced management team with expertise in SPAC transactions.
- Access to capital through public markets.
- Proprietary technology platform for developing cell therapies (post-merger).
- Strong intellectual property portfolio (post-merger).
What Are GXGX's Weaknesses?
No operating history or revenue prior to merger.
- Dependence on identifying and completing a successful merger.
- High expenses associated with SPAC structure.
- Negative profitability and high operating losses.
What Could Drive GXGX Stock Higher?
Completion of ongoing clinical trials for Celularity's cell therapies.
- Regulatory approvals for new cell therapy products.
- Expansion of Celularity's commercial operations and market reach.
- Strategic partnerships and collaborations with other companies.
- Investment in research and development to drive innovation.
What Are the Key Risks for GXGX?
Financial-distress signal — its Altman Z-Score of -8.04 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Celularity's cell therapies.
- Regulatory delays or rejections for new product approvals.
- Increased competition in the cell therapy market.
- Market volatility and economic downturn.
- Dependence on key personnel and intellectual property.
What Are the Growth Opportunities for GXGX?
- Celularity's growth is tied to the successful development and commercialization of its cellular medicine products. Timeline: Ongoing clinical trials and regulatory approvals will be key milestones. Competitive advantage: Celularity's proprietary technology platform and intellectual property portfolio position it to capture a significant share of this market.
- Expansion into new therapeutic areas represents a significant growth opportunity for Celularity. By leveraging its existing technology and expertise, the company can develop new cell therapies for a wider range of diseases and conditions. Timeline: Ongoing research and development efforts will drive this expansion. Market size: The potential market for new cell therapies is vast, encompassing numerous unmet medical needs. Competitive advantage: Celularity's ability to innovate and develop novel therapies will be crucial for success.
- Strategic partnerships and collaborations can accelerate Celularity's growth and expand its market reach. By partnering with other companies, the company can gain access to new technologies, expertise, and distribution channels. Timeline: Ongoing discussions and negotiations with potential partners. Market size: The impact of partnerships will depend on the specific terms and scope of each agreement. Competitive advantage: Celularity's ability to attract and retain high-quality partners will be essential.
- Geographic expansion into new markets represents another growth opportunity for Celularity. By expanding its operations into new regions, the company can tap into new customer bases and revenue streams. Timeline: Ongoing market research and planning efforts. Market size: The potential market for cell therapies varies by region, depending on factors such as healthcare infrastructure and regulatory environment. Competitive advantage: Celularity's ability to adapt its products and services to local market needs will be crucial for success.
- Increased investment in research and development is essential for Celularity's long-term growth. By investing in new technologies and therapies, the company can maintain its competitive edge and drive innovation. Timeline: Ongoing allocation of resources to R&D activities. Market size: The impact of R&D investments will depend on the success of new product development efforts. Competitive advantage: Celularity's ability to attract and retain top scientific talent will be crucial for success.
What Are GXGX's Competitive Advantages?
- Proprietary technology platform for developing cell therapies.
- Intellectual property portfolio protecting its products and processes.
- Established relationships with healthcare providers and patients.
- Experienced management team with expertise in biotechnology and finance.
What Does GXGX Do?
GX Acquisition Corp., now known as Celularity Inc. (GXGX), was initially formed as a blank check company, also known as a special purpose acquisition company (SPAC). Founded with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, GX Acquisition Corp. was essentially a shell company seeking a promising private entity to take public. The company itself was not engaged in any business operations and did not generate any revenue prior to identifying and merging with a target. The strategy of GX Acquisition Corp. was to leverage the expertise of its management team to identify and evaluate potential target companies, negotiate favorable terms, and complete a business combination that would create value for its shareholders. The company's focus was on identifying opportunities within various sectors, with the ultimate goal of bringing a compelling business to the public markets through the SPAC structure. Upon successfully merging with Celularity, GXGX transitioned from a shell company to a publicly traded entity operating in the biotechnology sector.
What Products and Services Does GXGX Offer?
- Identified and evaluated potential target companies for merger or acquisition.
- Negotiated terms and conditions for a business combination.
- Completed a merger with Celularity, a biotechnology company.
- Transitioned from a shell company to a publicly traded operating company.
- Focused on developing and commercializing cellular medicine products.
- Conducting clinical trials to evaluate the safety and efficacy of its therapies.
How Does GXGX Make Money?
- Focused on merging with a private company to bring it public.
- Generating revenue through the sale of cellular medicine products.
- Developing and licensing intellectual property related to cell therapies.
What Industry Does GXGX Operate In?
GX Acquisition Corp. operated within the financial services sector, specifically as a shell company or SPAC. The SPAC market has experienced significant growth in recent years, driven by the desire of private companies to access public markets more quickly and efficiently. The competitive landscape includes numerous SPACs seeking attractive merger targets. The success of GX Acquisition Corp. depended on its ability to differentiate itself from other SPACs by identifying and securing a compelling target company, which it did by merging with Celularity. Market trends in the SPAC sector include increased regulatory scrutiny and investor demand for greater transparency and due diligence.
Who Are GXGX's Key Customers?
- Healthcare providers who administer cell therapies to patients.
- Patients who receive cell therapies for various diseases and conditions.
- Pharmaceutical companies that may partner with Celularity to develop and commercialize its products.
Company Profile
Celularity Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York City, US. The company is led by CEO Jay R. Bloom. GXGX has traded publicly since 2019.
How Celularity Inc. Is Valued
Celularity Inc. carries a market capitalization of $1.48B, placing it in the small-cap category.
Key Financial Metrics
Return on equity for Celularity Inc. stands at 411.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -92.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Celularity Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.04 places it in the distress zone, a signal of elevated financial risk.
GXGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Celularity's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively as discussions around innovative therapies gain traction, reflecting optimism about their product pipeline.
- Analysts have noted increasing interest in the regenerative medicine sector, positioning Celularity favorably within a growing market.
- Recent partnerships and collaborations hint at expanding opportunities, enhancing the company's credibility and market reach.
Bear Case
- Concerns about the regulatory landscape for biotech companies could create headwinds, as any delays may impact timelines for product approvals.
- Social sentiment has also shown skepticism, with some community members questioning the scalability of Celularity's technology in a competitive space.
- Recent earnings reports have raised questions regarding cash burn rates, leading to fears about the company's financial sustainability in the short term.
- Market perception remains cautious due to broader economic uncertainties, which may affect investor appetite for biotech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GXGX Latest News
No recent news available for GXGX.
Classification
Industry Shell CompaniesLeadership: Jay R. Bloom
CEO
Jay R. Bloom is an experienced executive with a background in finance and investment management. He has held leadership positions at various financial institutions and has extensive experience in mergers and acquisitions, capital markets, and corporate strategy. Bloom's expertise in identifying and evaluating investment opportunities has been instrumental in the formation and execution of GX Acquisition Corp.'s business strategy. He has a strong track record of creating value for shareholders through strategic transactions and operational improvements.
Track Record: Under Jay R. Bloom's leadership, GX Acquisition Corp. successfully completed a merger with Celularity, a biotechnology company focused on developing and commercializing cellular medicine products. This transaction represents a significant milestone for GX Acquisition Corp. and positions the company for future growth in the rapidly evolving biotechnology sector. Bloom's strategic vision and execution skills were critical to the success of this transaction.
GXGX Financial Services Stock FAQ
What happened to Celularity Inc. (GXGX) stock?
Celularity Inc. (GXGX) no longer trades on public markets. It was delisted in July 2021. The figures below are historical and are not a current quote.
Can I still buy GXGX shares?
No. GXGX stopped trading on public markets in July 2021, so the shares are not available through a broker. Anything you see quoted for GXGX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before GXGX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Celularity Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Celularity Inc. do?
Celularity Inc., formerly GX Acquisition Corp., is a biotechnology company focused on developing and commercializing cellular medicine products. The company's proprietary technology platform enables it to harness the power of cells to treat a wide range of diseases and conditions. Celularity's products include cell therapies for cancer, infectious diseases, and degenerative diseases.
What are the main risks for GXGX?
The main risks for GXGX (Celularity Inc.) include clinical trial failures, regulatory delays or rejections, increased competition, market volatility, and dependence on key personnel and intellectual property. Clinical trial failures could significantly impact the company's product pipeline and future revenue potential. Regulatory delays or rejections could delay or prevent the commercialization of new products.
What regulatory challenges does Celularity Inc. face?
Celularity Inc. faces significant regulatory challenges inherent in the biotechnology industry, particularly concerning the development and commercialization of cell therapies. These challenges include navigating the complex approval processes of regulatory agencies like the FDA, ensuring compliance with current Good Manufacturing Practices (cGMP) for cell therapy production, and adhering to ethical guidelines for cell sourcing and handling.
How does GXGX's SPAC structure impact its financial performance?
GXGX's initial SPAC structure significantly impacted its financial performance, characterized by high initial expenses related to deal sourcing, due diligence, and the merger process with Celularity. As a SPAC, GXGX did not generate revenue until the merger was complete, and its financial performance was primarily driven by the costs associated with identifying and acquiring a target company.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.